Filing summary
Entity and period: The supplied filing identifies the registrant as Kintara Therapeutics, Inc. (Nasdaq: KTRA), not Tuhura Biosciences, Inc. It is a Form 10-Q for the quarter ended September 30, 2021, the first quarter of Kintara’s fiscal 2022. Financial amounts below are in U.S. dollars and, unless stated otherwise, in thousands.
Business context
Kintara is a clinical-stage oncology company with no product revenue to date. Its lead programs are VAL-083, being developed for glioblastoma (GBM), and REM-001, a photodynamic therapy being developed principally for cutaneous metastatic breast cancer. The filing is unaudited and notes that quarterly results are not necessarily indicative of full-year results.
Financial results and liquidity
| Metric | Quarter ended September 30, 2021 | Prior-year quarter / comparator |
|---|---|---|
| Revenue | None to date | None to date |
| Research and development expense | $3,793 | $1,357 |
| General and administrative expense | $2,178 | $1,534 |
| Net loss | $5,966 | $19,518 |
| Net loss attributable to common stockholders | $8,430 | $22,706 |
| Basic and diluted loss per share | $0.25 | $1.33 |
| Net cash used in operating activities | $5,073 | $4,110 |
| Cash and cash equivalents | $19,339 | $10,537 at June 30, 2021 |
| Working capital | $17,107 | $9,013 at June 30, 2021 |
| Total assets / total liabilities | $22,343 / $3,180 | $13,543 / $2,962 at June 30, 2021 |
There is no meaningful revenue or gross margin to report because the company has not generated revenue. The quarter’s net loss was substantially lower than the prior-year quarter, which included a $16,094 non-cash acquired in-process research and development charge and $500 of merger costs. Operating expenses nevertheless increased: R&D rose by $2,436 and G&A by $644, primarily due to clinical development, personnel, professional fees and share-based compensation.
Cash increased by $8,802 during the quarter, mainly because of $13,803 net proceeds from a September registered direct offering and $74 from warrant exercises; operating activities used $5,073. The balance sheet reports $3,180 of total liabilities, including accounts payable and accrued liabilities, related-party payables and a $179 milestone liability. No separate debt balance is shown at quarter-end.
Material changes, financing and dilution
- The September offering issued 7.2 million common shares, pre-funded warrants for 4.8 million shares and warrants for 12.0 million shares. It generated approximately $13.6 million net proceeds. The pre-funded warrants were exercised during the quarter.
- Common shares outstanding increased from 32.740 million at June 30 to 47.974 million at September 30; the filing reports 48.535 million outstanding as of November 11. The offering and outstanding warrants, options and convertible preferred stock create potential further dilution.
- Series C preferred stock dividends resulted in issuance of 1.698 million common shares and a $2.462 million charge attributable to common stockholders. The quarter’s loss per share therefore differs from net loss per share before preferred-stock dividends.
- R&D spending is expected by management to be higher in fiscal 2022 than in fiscal 2021 as the GBM AGILE study progresses and REM-001 development continues.
Outlook, management commentary and risks
- Going concern: Management states that substantial doubt exists about the company’s ability to continue as a going concern within one year from issuance of the financial statements. The company has an accumulated deficit of $119.655 million, is pre-revenue and expects to need additional financing. Management is pursuing equity financing and/or strategic partnerships, but gives no assurance these efforts will succeed.
- Runway: Including the September offering proceeds, management estimated cash would fund planned operations for less than one year from issuance, but expected it to fund the company through Stage 1 of the GBM AGILE study. Further development may be delayed, reduced or discontinued if additional capital is unavailable.
- Clinical outlook: Management’s targeted milestones included REM-001 IND reactivation in Q1 2022, first patient enrollment in its 15-patient confirmatory study in Q2 2022, and potential VAL-083 GBM AGILE Stage 1 graduation in Q3 2022. These are plans, not assurances.
- COVID-19 and execution: Kintara reported no significant COVID-related effect on enrollment or treatment in its VAL-083 studies to date, but reported delays in REM-001 contract manufacturing and supplies that could affect program timing. COVID-related capital-market uncertainty may also hinder fundraising.
- Clinical and regulatory risk: VAL-083 and REM-001 remain investigational. The reported Phase 2 outcomes were not from head-to-head trials; efficacy, safety, regulatory approval and commercialization remain uncertain. Myelosuppression, including thrombocytopenia and neutropenia, was the most common VAL-083 adverse event described.
- Contingencies and governance: Potential REM-001 milestone payments under the St. Cloud agreement total $1.0 million if specified clinical and regulatory events occur. The filing reports no legal proceedings and states disclosure controls were effective, with no material quarter-specific change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer and reporting period: the supplied text is Kintara Therapeutics’ 10-Q for the quarter ended September 30, 2021, despite the request metadata naming Tuhura Biosciences.
- Assess the company’s actual cash runway, quarterly cash burn and financing needs against its stated going-concern uncertainty and anticipated GBM AGILE spending.
- Review dilution from the September offering, outstanding warrants and options, and Series C preferred conversions and dividends.
- Track GBM AGILE enrollment, Stage 1 results and timing, and verify the basis and limitations of the cited Phase 2 topline data.
- Monitor REM-001 manufacturing delays, planned study start dates and any required financing or partnership arrangements.